MedTrace Logo

Treatment of Recurrent Pregnancy Loss Using Mesenchymal Stem Cells

NCT05520112 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-08-29

No results posted yet for this study

Summary

Treatment of Recurrent pregnancy loss using mesenchymal stem cells capable of differentiation in the endometrial-decidual direction.

Conditions

  • Recurrent Pregnancy Loss

Interventions

BIOLOGICAL

Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction

Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction

OTHER

Standard treatment according to the clinical protocols

Standard treatment of Recurrent Pregnancy Loss according to the clinical protocols

Sponsors & Collaborators

  • Belarusian Medical Academy of Post-Graduate Education

    collaborator OTHER

  • Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

    lead OTHER_GOV

Principal Investigators

  • Andrei Hancharou, Dr · Institute for biophysics and cellular engineering NAS of Belarus

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Belarus

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05520112 on ClinicalTrials.gov